| Literature DB >> 25274131 |
Moyez Jiwa1, Anne Long, Tim Shaw, Georgina Pagey, Georgia Halkett, Vinita Pillai, Xingqiong Meng.
Abstract
BACKGROUND: There has been a focus recently on the use of the Internet and email to deliver education interventions to general practitioners (GPs). The treatment of breast cancer may include surgery, radiotherapy, chemotherapy, and/or hormone treatment. These treatments may have acute adverse effects. GPs need more information on the diagnosis and management of specific adverse effects encountered immediately after cancer treatment.Entities:
Keywords: adverse effects; breast cancer; general practice; patient care planning; treatment
Mesh:
Year: 2014 PMID: 25274131 PMCID: PMC4213802 DOI: 10.2196/jmir.3585
Source DB: PubMed Journal: J Med Internet Res ISSN: 1438-8871 Impact factor: 5.428
Specific recommendations for management of symptoms or problems after treatment for breast cancer.
| Symptom or problem | Adverse effect | |||
|
| Mild | Moderate | Severe | |
|
|
|
|
| |
|
| Characterized by | Slight fluctuant swelling in operative site | Obvious fluctuant swelling in operative site | Tense (nonfluctuant) and uncomfortable swelling in operative site |
|
| Action to be taken by GP | Arrange for patient to see surgeon within 7 days | Arrange for patient to see surgeon within 4 days | Arrange for patient to see surgeon within 2 to 3 d |
|
| All the following: | Any of the following: | Any of the following: | |
|
| Characterized by | Fever <38 °C | Fever >38 °C | Fever >38 °C |
|
| Action if <7 d or >14 d since chemotherapy | See patient <48 h | See patient <24 h | Call medical oncologist. Send immediately to closest emergency department (ED). If patient from rural area and closest hospital >2 h away, consider giving IV/IM broad spectrum antibiotic prior to sending |
|
| Action if 7-14 d since chemotherapy | See patient <24 h | Call medical oncologist | Call medical oncologist |
|
| ≤4/d | 5-8/d | >8/d±abdominal pain or dehydrated and cannot cope at home | |
|
| Action to be taken | See patient <48 h | See patient <24 h | Call medical oncologist |
|
|
|
|
| |
|
| Characterized by | ≤ 6/d still managing oral intake | 7-10/d with mild oral intake | >10/d no oral intake |
|
| Action to be taken | See patient <48 h | See patient < 24 h | Call medical oncologist and consider admission |
|
| All of the following | Any of the following | Any of the following | |
|
| Characterized by | Faint skin erythema ± dry desquamation ± moderate pruritus | Brisk erythema ± patchy moist desquamation limited to skin folds/creases | Confluent moist desquamation ± erythema extending beyond treatment area ± systemically unwell |
|
| Action to be taken | Avoid additional skin irritants (eg, sun exposure, perfumed soaps/perfumes, adhesive tapes) | As above re: avoidance of skin irritants, simple hygiene, measures and analgesics | Analgesia as appropriate |
|
|
|
|
| |
|
| Characterized by | ≤2 d of nil/minimal BM | 3-5 d of nil/minimal BM | >5 d of nil/minimal BM ± colic |
|
| Action to be taken | Recommend docusate sodium & senna II bid and or macrogol 3350 sachet I bid and glycerine suppository | Increase docusate sodium and senna and macrogol 3350 consider addition of sorbitol etc or Macrogol AND sodium citrate suppositories | Call medical oncologist |
Participant demographic information (N=50).
| GP characteristics | Study sample | National populationa | |||
|
|
| Mean | % | ||
|
|
|
|
| ||
|
| Age (years), mean (SD) | 43.4 (11.0) | 50.5 |
| |
|
| Years after graduation, mean (SD) | 19.5 (11.2) |
|
| |
|
| Years of GP experience, mean (SD) | 14.8 (11.3) |
|
| |
|
| GPs at primary clinic, mean (SD) | 7.7 (4.0) |
|
| |
|
| GP sessions worked/week (n=48), mean (SD) | 6.5 (3.1) |
|
| |
|
|
|
|
|
| |
|
|
| Male | 24 (48) |
| 60.9 |
|
|
| Female | 26 (52) |
|
|
|
| Graduated in Australia, n (%) | 38 (76) |
| 65.9 | |
|
| Registrars (GPs in training), n (%) | 9 (18) |
| 3.8 | |
|
| FRACGP (Fellows of the Royal Australian College of GPs), n (%) | 30 (60) |
| 56.8 | |
|
|
|
|
| ||
|
| Accredited, n (%) | 49 (98) |
| 88.6 | |
|
|
|
|
|
| |
|
|
| Australian Capital Territory | 1 (2) |
| 1.5 |
|
|
| New South Wales | 7 (14) |
| 33.1 |
|
|
| Queensland | 3 (6) |
| 19.5 |
|
|
| South Australia | 6 (12) |
| 8.4 |
|
|
| Victoria | 13 (26) |
| 25.1 |
|
|
| Western Australia | 20 (40) |
| 9.1 |
|
|
|
|
|
| |
|
|
| Major city | 38 (76) |
| 71.1 |
|
|
| Nonmajor city | 12 (24) |
| 28.9 |
|
|
|
|
|
| |
|
|
| Principal | 9 (18) |
|
|
|
|
| Nonprincipal | 32 (64) |
|
|
|
|
| Others | 9 (18) |
|
|
|
|
|
|
| ||
|
|
|
|
|
| |
|
|
| <100 | 27 (54) |
|
|
|
|
| 100-149 | 14 (28) |
|
|
|
|
| ≥150 | 9 (18) |
|
|
|
|
|
|
|
| |
|
|
| <11 | 7 (14) |
| 1.2 |
|
|
| 11-20 | 8 (16) |
| 12.2 |
|
|
| 21-40 | 27 (54) |
| 53 |
|
|
| ≥41 | 8 (16) |
| 33.5 |
|
|
|
|
|
| |
|
|
| No | 43 (86) |
|
|
|
|
| Yes, <25% | 7 (14) |
| 24.5 |
aSourced from national data when available [18-20].
Correct diagnosis of cases per phase of study (N=50).
| Diagnosis | Phase 1, n (%) | Phase 2, n (%) |
|
| Constipation | 40 (80) | 39 (78) | .80 |
| Diarrhea | 46 (92) | 50 (100) | .046 |
| Radiation dermatitis | 47 (94) | 47 (94) | >0.99 |
| Postchemotherapy infection | 44 (88) | 49 (98) | .03 |
| Postoperative seroma | 31 (62) | 49 (98) | <.001 |
| Vomiting | 47 (94) | 50 (100) | .08 |
| Total (n=300) | 255 (85.0) | 284 (94.7) | <.001 |
a P values derived from McNemar test.
Correct management of cases by phase of study (N=50).a
| Management | Phase 1, n (%) | Phase 2, n (%) |
| |
|
|
|
|
| |
|
| Refer to oncologist | 3 (6) | 8 (16) | .14 |
|
| Prescribe medication | 38 (76) | 44 (88) | .11 |
|
|
|
|
| |
|
| Prescribe Medication | 32 (64) | 45 (90) | .003 |
|
|
|
|
| |
|
| Refer to breast care nurse / radiation oncologist / specialist | 33 (66) | 25 (50) | .09 |
|
| Prescribe specific creams | 3 (6) | 19 (38) | <.001 |
|
| Advise patient | 13 (26) | 38 (76) | <.001 |
|
|
|
|
| |
|
| Refer to oncologist | 18 (36) | 27 (54) | .07 |
|
| Collect throat swab | 18 (36) | 33 (66) | .003 |
|
|
|
|
| |
|
| Refer to surgeon | 23 (46) | 40 (80) | .001 |
|
| Organize ultrasound | 35 (70) | 39 (78) | .32 |
|
| Aspiration | 16 (32) | 13 (26) | .49 |
|
|
|
|
| |
|
| Refer to oncologist | 20 (40) | 5 (10) | <.001 |
|
| Prescribe medication | 22 (44) | 46 (92) | <.001 |
|
| Order tests | 20 (40) | 4 (8) | <.001 |
aIn each case there is more than 1 correct answer.
b P values derived from McNemar test.
Factors associated with incorrect management (inconsistent with expert opinion) in phase 1 (N=50).
| Explanatory variable | Inappropriate referral | Inappropriate prescription | Unnecessary tests | ||||
|
| OR (95% CI) |
| OR (95% CI) |
| OR (95% CI) |
| |
| Age | — |
| — |
| 0.98 (0.96, 1.00) | .04 | |
| GP sessions worked/week | — |
| 1.12 (1.03, 1.22) | .008 | — |
| |
|
| — |
|
|
| — |
| |
|
| Female |
|
| 1.00 |
|
|
|
|
| Male |
|
| 0.44 (0.26, 0.74) | .002 |
|
|
|
|
|
| — |
| — |
| |
|
| No | 1.00 |
|
|
|
|
|
|
| Yes | 0.47 (0.23, 0.97) | .04 |
|
|
|
|
|
| — |
| — |
|
|
| |
|
| <21 |
|
|
|
| 1.00 |
|
|
| 21-40 |
|
|
|
| 1.87 (1.08, 3.22) | .03 |
|
| >41 |
|
|
|
| 2.01 (1.14, 3.56) | .02 |
|
| — |
|
|
| — |
| |
|
| Principal |
|
| 1.00 |
|
|
|
|
| Nonprincipal |
|
| 0.49 (0.21, 1.11) | .09 |
|
|
|
| Others |
|
| 0.25 (0.09, 0.71) | .009 |
|
|
|
|
|
|
|
|
|
| |
|
| Constipation | 1.00 |
| 1.00 |
| 1.00 |
|
|
| Diarrhea | 0.29 (0.07, 1.25) | .10 | 1.90 (0.78, 4.62) | .16 | 15.92 (6.11, 41.47) | <.001 |
|
| Radiation dermatitis | 0.03 (0.01, 0.11) | <.001 | 59.41 (14.05, 251.26) | <.001 | 2.19 (0.88, 5.46) | .09 |
|
| Postchemotherapy infection | 0.11 (0.03, 0.38) | <.001 | 4.66 (1.82, 11.91) | .001 | 3.15 (1.23, 8.07) | .02 |
|
| Postoperative seroma | 0.07 (0.02, 0.30) | <.001 | 0, 30 (0.08, 1.04) | .06 | 1.62 (0.53, 5.00) | .40 |
|
| Vomiting | 0.09 (0.03, 0.32) | <.001 | 4.66 (1.90, 11.43) | .001 | 7.32 (2.49, 21.59) | <.001 |
Incorrect management by phase.
| Management | Phase 1, n (%) | Phase 2, n (%) |
|
| Refer to specialist | 194 (64.7) | 148 (49.3) | <.001 |
| Prescription | 138 (46.0) | 76 (25.3) | <.001 |
| Order test | 126 (42.0) | 103 (34.3) | .03 |
a P values derived from McNemar test.